Immunic Stock Analysis
| IMUX Stock | USD 1.06 0.04 3.92% |
IPO Date 17th of April 2014 | 200 Day MA 0.7944 | 50 Day MA 0.6935 | Beta 1.588 |
Immunic holds a debt-to-equity ratio of 0.01. Short and Long Term Debt Total is likely to drop to about 101.7 K in 2026. Net Debt is likely to drop to about (16.1 M) in 2026 With a high degree of financial leverage come high-interest payments, which usually reduce Immunic's Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
Immunic's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Immunic's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Immunic Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Immunic's stakeholders.
For many companies, including Immunic, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Immunic, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Immunic's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 11.6859 | Book Value (0.06) | Enterprise Value | Enterprise Value Ebitda 0.2135 | Shares Float 121.1 M |
Immunic is undervalued with Real Value of 1.94 and Target Price of 4.88. The main objective of Immunic stock analysis is to determine its intrinsic value, which is an estimate of what Immunic is worth, separate from its market price. There are two main types of Immunic's stock analysis: fundamental analysis and technical analysis.
The Immunic stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Immunic is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day ( substitute day ), Independence Day. Immunic Stock trading window is adjusted to America/New York timezone.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. Immunic Stock Analysis Notes
About 62.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.8. Immunic last dividend was issued on the 15th of April 2019. The entity had 1:40 split on the 15th of April 2019. Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. t and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 65 people. To learn more about Immunic call Daniel Vitt at 332 255 9818 or check out https://imux.com.Immunic Investment Alerts
| Immunic is way too risky over 90 days horizon | |
| Immunic has some characteristics of a very speculative penny stock | |
| Immunic appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (97.17 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Immunic currently holds about 72.77 M in cash with (85.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.85, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Immunic has a frail financial position based on the latest SEC disclosures | |
| Roughly 62.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Key Opinion Leader Panel to Discuss Acrivons ACR-368 Endometrial Cancer Trial during the 2026 European Society of Gynecological Oncology Congress |
Immunic Largest EPS Surprises
Earnings surprises can significantly impact Immunic's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-11-13 | 2025-09-30 | -0.15 | -0.13 | 0.02 | 13 | ||
2026-02-19 | 2025-12-31 | -0.0944 | -0.07 | 0.0244 | 25 | ||
2025-08-07 | 2025-06-30 | -0.17 | -0.2 | -0.03 | 17 |
Immunic Stock Institutional Investors
| Shares | Ikarian Capital, Llc | 2025-09-30 | 914.2 K | Blackrock Inc | 2025-09-30 | 725.7 K | Citadel Advisors Llc | 2025-09-30 | 535.1 K | Marshall Wace Asset Management Ltd | 2025-09-30 | 533.5 K | Millennium Management Llc | 2025-09-30 | 530.5 K | Gsa Capital Partners Llp | 2025-12-31 | 527.5 K | Squarepoint Ops Llc | 2025-12-31 | 352.9 K | State Street Corp | 2025-09-30 | 331.9 K | Northern Trust Corp | 2025-09-30 | 211.3 K | Aberdeen Group Plc | 2025-12-31 | 8.2 M | Bvf Inc | 2025-12-31 | 7.7 M |
Immunic Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 122.69 M.Immunic Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (4.04) | (3.84) | |
| Return On Capital Employed | 15.72 | 14.94 | |
| Return On Assets | (4.04) | (3.84) | |
| Return On Equity | 14.56 | 15.29 |
Management Efficiency
Immunic has return on total asset (ROA) of (1.9876) % which means that it has lost $1.9876 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (16.5315) %, meaning that it created substantial loss on money invested by shareholders. Immunic's management efficiency ratios could be used to measure how well Immunic manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 15.29 in 2026, despite the fact that Return On Tangible Assets are likely to grow to (3.84). Non Currrent Assets Other is likely to rise to about 51.9 K in 2026, whereas Total Assets are likely to drop slightly above 22.8 M in 2026.| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | (8.41) | (7.99) | |
| Price Book Value Ratio | (124.52) | (118.29) | |
| Enterprise Value Multiple | (8.41) | (7.99) | |
| Price Fair Value | (124.52) | (118.29) | |
| Enterprise Value | 734.5 M | 771.2 M |
Immunic benefits from a management team that prioritizes both innovation and efficiency. We analyze these priorities to gauge the stock's future performance.
Technical Drivers
As of the 3rd of March, Immunic retains the Market Risk Adjusted Performance of 3.4, risk adjusted performance of 0.1189, and Downside Deviation of 4.63. Immunic technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Immunic Price Movement Analysis
The output start index for this execution was two with a total number of output elements of fifty-nine. The Double Exponential Moving Average indicator was developed by Patrick Mulloy. It consists of a single exponential moving average and a double exponential moving average. This indicator is more responsive to Immunic changes than the simple moving average.
Immunic Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immunic insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immunic's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Immunic insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Immunic Outstanding Bonds
Immunic issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Immunic uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Immunic bonds can be classified according to their maturity, which is the date when Immunic has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Immunic Predictive Daily Indicators
Immunic intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Immunic stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Immunic Forecast Models
Immunic's time-series forecasting models are one of many Immunic's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Immunic's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Immunic Bond Ratings
Immunic financial ratings play a critical role in determining how much Immunic have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Immunic's borrowing costs.| Piotroski F Score | 3 | Frail | View |
| Beneish M Score | (7.51) | Unlikely Manipulator | View |
Immunic Debt to Cash Allocation
As Immunic follows its natural business cycle, the capital allocation decisions will not magically go away. Immunic's decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors.
Immunic currently holds 107 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Immunic has a current ratio of 7.38, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Immunic's use of debt, we should always consider it together with its cash and equity.Immunic Total Assets Over Time
Immunic Assets Financed by Debt
The debt-to-assets ratio shows the degree to which Immunic uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.Immunic Debt Ratio | 2.7 |
Immunic Corporate Bonds Issued
Immunic Short Long Term Debt Total
Short Long Term Debt Total |
|
About Immunic Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Immunic prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Immunic shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Immunic. By using and applying Immunic Stock analysis, traders can create a robust methodology for identifying Immunic entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | -5.8 K | -6.1 K | |
| Operating Profit Margin | -5.9 K | -6.2 K | |
| Net Loss | -5.8 K | -6.1 K | |
| Gross Profit Margin | (256.77) | (269.61) |
Current Immunic Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Immunic analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Immunic analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Consensus | # of Analysts | |
| 4.88 | Strong Buy | 7 | Odds |
Most Immunic analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Immunic stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Immunic, talking to its executives and customers, or listening to Immunic conference calls.
Immunic Stock Analysis Indicators
Immunic stock analysis indicators help investors evaluate how Immunic stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Immunic shares will generate the highest return on investment. By understating and applying Immunic stock analysis, traders can identify Immunic position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 35.7 M | |
| Common Stock Shares Outstanding | 1.6 B | |
| Total Stockholder Equity | -6.7 M | |
| Total Cashflows From Investing Activities | -161 K | |
| Property Plant And Equipment Net | 1.2 M | |
| Cash And Short Term Investments | 15.5 M | |
| Cash | 15.5 M | |
| Accounts Payable | 10.1 M | |
| Net Debt | -15.4 M | |
| 50 Day M A | 0.6935 | |
| Total Current Liabilities | 30.6 M | |
| Non Current Assets Total | 1.2 M | |
| Stock Based Compensation | 8.9 M |
Additional Tools for Immunic Stock Analysis
When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.